Product image of Jeligo (Linagliptin) supplied by GNH India

Jeligo

Active Ingredient:
Linagliptin
Origin:
EU

Jeligo (Linagliptin)

Linagliptin, the active ingredient in Jeligo, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus when diet, exercise, and other therapies are insufficient.

GNH India supplies Jeligo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. Its distribution network ensures timely delivery and regulatory compliance across multiple regions.

Manufacturer / TM Owner

Egis Pharmaceuticals Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is used to manage hyperglycemia in the type 2 diabetes mellitus pathway.

  • Type 2 diabetes mellitus: improves glycemic control as monotherapy or in combination with other antidiabetic agents.
  • Adjunct to diet and exercise: helps patients achieve target HbA1c when lifestyle measures alone are insufficient.
  • Combination therapy: used alongside metformin, sulfonylureas, or insulin to enhance overall glucose management.

How It Works

  • Linagliptin selectively and reversibly inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme, which degrades the incretin hormones GLP-1 and GIP. By blocking DPP-4, linagliptin increases endogenous incretin levels, enhancing glucose-dependent insulin secretion and suppressing glucagon release, thereby lowering post-prandial and fasting blood glucose concentrations without causing hypoglycemia in the absence of other agents.

Side Effects

Linagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nose and throat.
  • Headache: transient cranial pain.
  • Dizziness: sensation of light-headedness.
  • Gastrointestinal discomfort: nausea, abdominal pain or diarrhea.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe hypersensitivity reactions: skin rash, angioedema, or anaphylaxis.
  • Hepatic injury: marked elevation of liver enzymes or jaundice.

Precautions & Warnings

Before initiating therapy, clinicians should consider several precautionary measures.

  • Renal function: assess baseline and monitor periodically, especially in patients with impairment.
  • Pancreatitis risk: discontinue if signs of acute pancreatitis appear.
  • Hepatic monitoring: evaluate liver enzymes before initiation and during therapy.
  • Cardiovascular status: use cautiously in patients with a history of heart failure.
  • Hypersensitivity: avoid in individuals with known allergy to linagliptin or DPP-4 inhibitors.
  • Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Avoid Interactions

Linagliptin can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin effectiveness.
  • Concurrent use with insulin or sulfonylureas: heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Diuretics: may potentiate blood pressure changes; monitor electrolytes.
  • Antihypertensive agents: additive blood pressure lowering effect; observe hemodynamic status.

Frequently Asked Questions

Jeligo contains linagliptin, a DPP-4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It helps lower blood glucose levels by enhancing the body's own incretin response when diet and exercise alone are not sufficient.

Linagliptin blocks the dipeptidyl peptidase‑4 enzyme, preventing the breakdown of incretin hormones GLP‑1 and GIP. This increases insulin secretion and reduces glucagon release in a glucose‑dependent manner, improving overall glycemic control.

The appropriate dose of Jeligo is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for linagliptin in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified clinician.

To order Jeligo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jeligo (linagliptin) is a non‑peptidic DPP-4 inhibitor with a long half‑life that allows once‑daily dosing without dose adjustment in renal impairment, unlike some other agents that may require renal dose modifications.

Store Jeligo tablets at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

Jeligo is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious adverse events include pancreatitis, severe hypersensitivity reactions such as angioedema or anaphylaxis, and significant liver injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or jaundice.

Jeligo should be avoided in individuals with known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for patients with a history of pancreatitis, severe hepatic impairment, or uncontrolled heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT